Table 2. Research indices at baseline.
| Group 1 surgery only (n=16) | Group 2 surgery plus standard chemotherapy (n=32) | Group 3 surgery plus standard chemotherapy and anti-VEGF therapy (n=20) | P-value | |
|---|---|---|---|---|
| Circulating endothelial cells (cells ml−1) | 4 (0–19) | 12 (0–19) | 11 (7–48) | 0.746 |
| Endothelial progenitor cells (cells ml−1) | 13 (0–39) | 16 (9–44) | 21 (10–39) | 0.749 |
| Von Willebrand factor (IU dl−1) | 115 (22) | 123 (33) | 121 (30) | 0.659 |
| Soluble E selectin (ng ml−1) | 31 (9) | 34 (12)* | 26 (8)* | 0.029 |
| VEGF (pg ml−1) | 120 (10–494) | 320 (30–1200) | 500 (40–1000) | 0.160 |
| Angiogenin (ng ml−1) | 308 (75) | 282 (97) | 319 (97) | 0.231 |
| CD34+ve cells (cells ml−1) | 849 (638–1167) | 781 (417–1315) | 781 (585–1123) | 0.839 |
| White cell count (x106 ml−1) | 6.7 (1.6) | 7.9 (2.2) | 6.7 (1.5) | 0.046a |
Data are mean (s.d.) or median (interquartile range). Analysed by ANOVA, *P<0.05 (Tukey's post hoc test).
Reference ranges from a control population (reference 34) are circulating endothelial cells 0 (0–8), endothelial progenitor cells 7 (0–12), von Willebrand factor 110 (31), soluble E selectin 22 (10), VEGF 32 (0–82), angiogenin 143(107–175) and white cell count 5.8 (1.3). We do not have a reference range for CD34+ve cells.
a
No significant inter-group differences.